ClickHouse Acquires HyperDX to Accelerate the Future of Observability

13.3.2025 16:00:00 CET | Business Wire | Press Release

ClickHouse, the company behind the world's fastest analytical database, today announced the acquisition of HyperDX, an open-source observability platform built on ClickHouse. This strategic acquisition reinforces ClickHouse's commitment to delivering the fastest, most cost-effective, and scalable solutions to developers and enterprises worldwide; including observability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250313954782/en/

ClickHouse, the company behind the world's fastest analytical database, today announced the acquisition of HyperDX, an open-source observability platform built on ClickHouse. (Graphic: Business Wire)

The acquisition combines ClickHouse's unmatched performance and scalability with HyperDX's developer-first experience, creating a comprehensive observability platform that seamlessly integrates session replay, exceptions, logs, infrastructure metrics, and distributed tracing through an OpenTelemetry-native approach.

“ClickHouse’s analytics capabilities and open ecosystem make it a powerful technology for observability. However, the end-user experience lacked some of the comprehensive features of more established solutions. HyperDX is very exciting, bringing together an enhanced query experience with a more intuitive UI for exploratory observability workflows.”
Viktor Eriksson, Lovable

"Observability is fundamentally a data problem," said Tanya Bragin, VP of Product & Marketing at ClickHouse. "The dataset size dictates how difficult and expensive it will be to build an observability platform. That's why ClickHouse has been the backbone of observability platforms for years, powering logging, metrics, and tracing solutions at companies like eBay and Netflix."

ClickHouse originally explored new observability solutions while transitioning from Datadog to their in-house LogHouse stack (How we Built a 19 PiB Logging Platform with ClickHouse and Saved Millions), which was built on ClickHouse to handle their petabyte-scale workloads. During this process, they discovered HyperDX and saw how easily it could transform an existing ClickHouse deployment into a full observability platform.

"When we started HyperDX, we had two core beliefs: we wanted to build the best open-source observability platform, and ClickHouse was the ONLY database to power it," said Michael Shi, CEO at HyperDX. "Our mission has always been to help engineers diagnose and resolve production issues faster, and ClickHouse has been a foundational part of that journey from day one."

The Future of Open-Source Observability

Through conversations, the companies discovered they shared the same vision:

Observability should be cost-effective and developer-friendly
ClickHouse's performance and scalability make it the best foundation for observability
HyperDX's developer-first experience makes it effortless for teams to implement

The integration provides numerous benefits, including:

Standards-Based Data Collection – Both ClickHouse and HyperDX are committed to OpenTelemetry, with ClickHouse now maintaining the ClickHouse OpenTelemetry exporter
Open-Source First – Making robust observability accessible to everyone, with cloud offerings providing a simple, cost-effective operational experience
Flexible Data Access – Direct access to observability data with multiple analysis options
Blazing Fast Performance – Query terabytes in seconds for real-time troubleshooting

HyperDX Cloud will continue serving and onboarding new customers, and the open-source project will remain actively maintained and developed. At the same time, the joint roadmap focuses on bringing even more powerful observability tools to engineers.

Getting Started

Explore more details on the ClickHouse Blog (ClickHouse acquires HyperDX: the future of open-source observability) or the HyperDX blog (ClickHouse acquires HyperDX to accelerate the future of open-source observability).

If you want to try HyperDX, you can get started for free on our cloud or self-host it on your own infrastructure.

About ClickHouse

ClickHouse is the company behind the world's fastest open-source analytical database management system. Used by companies including eBay, Netflix, and Cloudflare, ClickHouse enables the processing of petabyte-scale datasets with unmatched efficiency and cost-effectiveness.

About HyperDX

HyperDX is an open-source observability platform built on ClickHouse that provides a seamless OpenTelemetry-native experience. It integrates session replay, exceptions, logs, infrastructure metrics, and distributed tracing to help engineers diagnose and resolve production issues faster.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250313954782/en/

Contacts

Tyler Hannan
ClickHouse
tyler@clickhouse.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom